The Financial Times highlights UCLB spinout’s cancer progress

The Financial Times has run a piece highlighting UCLB spinout Autolus’ journey to produce therapies for cancer side effects. 

The news story focuses on the work taking place at Autolus’ Stevenage facility, which is manufacturing the latest generation of an innovative, personalised cancer treatment: a new Car-T cell therapy to treat the blood cancer acute lymphoblastic leukaemia after it received the green light from the US Food and Drug Administration in November. 

The first Car-T therapies were approved in 2017 and they remain one of the most personalised medicines in oncology, leading to long-term remission for some patients. They are made by taking immune system cells from an individual patient, re-engineering immune system cells from an individual patient, re-engineering them to kill tumours more effectively and putting them back into that patient. 

The article covers the challenges faced bringing such therapies to market.

Read the article, which requires a subscription, here.